Skip to main content

Table 3 Summary of the multivariable analyses of prognostic factors after propensity score matching

From: Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis

Variable OS DSS DMFS LRFS
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
IC regimen (PF vs. TPF) 0.581 (0.371–0.910) 0.018 0.543 (0.343–0.859) 0.009 0.551 (0.357–0.850) 0.007 1.179 (0.667–2.084) 0.572
Gender (male vs. female) 1.166 (0.679–2.004) 0.578 1.069 (0.613–1.861) 0.815 1.065 (0.623–1.818) 0.819 0.935 (0.450–1.939) 0.856
Age 1.026 (1.006–1.046) 0.010 1.024 (1.004–1.044) 0.017 1.013 (0.994–1.033) 0.173 1.014 (0.987–1.041) 0.308
Smoking (yes vs. no) 1.020 (0.616–1.687) 0.939 1.004 (0.604–1.667) 0.989 1.118 (0.685–1.823) 0.656 1.061 (0.555–2.028) 0.857
T stage (T1–2 vs. T3–4) 1.349 (0.866–2.101) 0.185 1.345 (0.863–2.096) 0.191 1.449 (1.056–1.987) 0.021 1.434 (0.752–2.733) 0.274
N stage (N0–1 vs. N2–3) 1.285 (0.975–1.693) 0.075 1.319 (0.995–1.748) 0.054 1.652 (1.278–2.134) 0.001 1.125 (0.778–1.627) 0.532
Clinical stage (III vs. IV) 2.193 (1.419–3.390) 0.001 2.277 (1.459–3.552) 0.001 1.137 (0.663–1.042) 0.667 0.891 (0.386–2.057) 0.787
Radiation technique (IMRT vs. 2D-CRT) 1.835 (1.153–2.919) 0.010 1.859 (1.159–2.982) 0.010 2.152 (1.370–3.380) 0.001 1.089 (0.550–2.156) 0.807
  1. IC induction chemotherapy, TPF taxane, cisplatin and 5-fluorouracil, PF cisplatin and 5-fluorouracil, CDDP dose the cisplatin dose of concurrent chemotherapy, IMRT intensity-modulated radiotherapy, 2D-CRT two-dimensional radiotherapy, RT radiotherapy, HR hazard ratio